Extended Hypofractionated Cancer Radiation Therapy Against Aged and Non-aged Breast Carcinomas Patients


  •   Rawshan Ara Khatun

  •   Julekha Khatun

  •   Kutub Uddin Ahamed


We led an investigation to decide if hypo fractionated 35-days timetable of entire breast radiation is pretty much as viable. Women who bearing obtrusive breast carcinoma had gone through breast monitoring a medical procedure and resection edges were clean and partially lymph hubs were negatively approached with haphazardly relegated to get entire bosom illumination either at a control portion of 50 Gy in 15 divisions over a time of 45 days or at a portion of 45.5 Gy in 12 parts over a time of 22 days (the hypo fractionated-radiation bunch). The repetition at 36 months were 7.2% among the 301 ladies allocated to standard illumination as contrasted and 7.6% among the 312 ladies allocated to the hypo fractionated routine. At 36 months, 69.5% of ladies in the benchmark group as contrasted and 71.2% of the ladies in the hypo fractionated-radiation bunch had a decent or astounding restorative result. 3 years after therapy, sped up, hypo fractionated entire breast illumination was not sub-par compared to standard radiation therapy in ladies who had gone through breast preserving a medical procedure for obtrusive bosom malignant growth with clear careful edges what's more, negative axillary hubs. The ideal fractionation plan for entire bosom light after bosom rationing medical procedure is obscure.

Keywords: Hypofractionated-radiation, breast cancer, conserving surgery, mastectomy, Clinical Oncology


B. Fisher, J.-H. Jeong, S. Anderson, J. Bryant, E. R. Fisher, and N. Wolmark, “Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation.,” N. Engl. J. Med., vol. 347, no. 8, pp. 567–575, Aug. 2002, doi: 10.1056/NEJMoa020128.

B. Fisher et al., “Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer.,” N. Engl. J. Med., vol. 320, no. 13, pp. 822–828, Mar. 1989, doi: 10.1056/NEJM198903303201302.

A. Bhatt, K. Sowards, G. Bhatt, A. Freeman, and A. Dragun, “Impact of interfraction seroma collection on breast brachytherapy dosimetry - a mathematical model.,” J. Contemp. Brachytherapy, vol. 4, no. 2, pp. 101–105, Jun. 2012, doi: 10.5114/jcb.2012.29366.

S. W. Yoon et al., “Per-fraction positional and dosimetric performance of prone breast tangential radiotherapy on HalcyonTM linear accelerator assessed with daily rapid kilo-voltage cone beam computed tomography: a single-institution pilot study.,” Radiat. Oncol., vol. 15, no. 1, p. 258, Nov. 2020, doi: 10.1186/s13014-020-01700-6.

G. Curigliano et al., “De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.,” Ann. Oncol. Off. J. Eur. Soc. Med. Oncol., vol. 28, no. 8, pp. 1700–1712, Aug. 2017, doi: 10.1093/annonc/mdx308.

A. Gupta, N. Ohri, and B. G. Haffty, “Hypofractionated radiation treatment in the management of breast cancer.,” Expert Rev. Anticancer Ther., vol. 18, no. 8, pp. 793–803, Aug. 2018, doi: 10.1080/14737140.2018.1489245.

J. Y. Lin et al., “Full axillary lymph node dissection and increased breast epidermal thickness 1 year after radiation therapy for breast cancer.,” J. Surg. Oncol., vol. 120, no. 8, pp. 1397–1403, Dec. 2019, doi: 10.1002/jso.25757.

J. Boyages and L. Baker, “Evolution of radiotherapy techniques in breast conservation treatment.” Gland Surg., vol. 7, no. 6, pp. 576–595, Dec. 2018, doi: 10.21037/gs.2018.11.10.

N. Aibe et al., “Results of a nationwide survey on Japanese clinical practice in breast-conserving radiotherapy for breast cancer.” J. Radiat. Res., vol. 60, no. 1, pp. 142–149, Jan. 2019, doi: 10.1093/jrr/rry095.

J. Sanz et al., “Once-Weekly Hypofractionated Radiotherapy for Breast Cancer in Elderly Patients: Efficacy and Tolerance in 486 Patients.” Biomed Res. Int., vol. 2018, p. 8321871, 2018, doi: 10.1155/2018/8321871.

S. F. Shaitelman et al., “Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial.,” JAMA Oncol., vol. 1, no. 7, pp. 931–941, Oct. 2015, doi: 10.1001/jamaoncol.2015.2666.

S. Chatterjee and S. Chakraborty, “Hypofractionated radiation therapy comparing a standard radiotherapy schedule (over 3 weeks) with a novel 1-week schedule in adjuvant breast cancer: an open-label randomized controlled study (HYPORT-Adjuvant)-study protocol for a multicentre, randomized ,” Trials, vol. 21, no. 1, p. 819, Sep. 2020, doi: 10.1186/s13063-020-04751-y.

H. Kim et al., “Prognostic Impact of Elective Supraclavicular Nodal Irradiation for Patients with N1 Breast Cancer after Lumpectomy and Anthracycline Plus Taxane-Based Chemotherapy (KROG 1418): A Multicenter Case-Controlled Study.,” Cancer Res. Treat., vol. 49, no. 4, pp. 970–980, Oct. 2017, doi: 10.4143/crt.2016.382.

E. F. Gillespie et al., “Geographic Disparity in the Use of Hypofractionated Radiation Therapy among Elderly Women Undergoing Breast Conservation for Invasive Breast Cancer.” Int. J. Radiat. Oncol. Biol. Phys., vol. 96, no. 2, pp. 251–258, Oct. 2016, doi: 10.1016/j.ijrobp.2016.05.006.

K. J. Ray, N. R. Sibson, and A. E. Kiltie, “Treatment of Breast and Prostate Cancer by Hypofractionated Radiotherapy: Potential Risks and Benefits.” Clin. Oncol. (R. Coll. Radiol)., vol. 27, no. 7, pp. 420–426, Jul. 2015, doi: 10.1016/j.clon.2015.02.008.

J.-C. Trone et al., “Assessment of non-inferiority with meta-analysis: example of hypofractionated radiation therapy in breast and prostate cancer.,” Sci. Rep., vol. 10, no. 1, p. 15415, Sep. 2020, doi: 10.1038/s41598-020-72088-2.

B. E. Hickey, M. Lehman, D. P. Francis, and A. M. See, “Partial breast irradiation for early breast cancer.,” Cochrane database Syst. Rev., vol. 7, no. 7, p. CD007077, Jul. 2016, doi: 10.1002/14651858.CD007077.pub3.

G. Henke et al., “Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial.,” Trials, vol. 19, no. 1, p. 667, Dec. 2018, doi: 10.1186/s13063-018-3021-9.

F. Sedlmayer et al., “Intraoperative radiotherapy (IORT) as boost in breast cancer.” Radiat. Oncol., vol. 12, no. 1, p. 23, Jan. 2017, doi: 10.1186/s13014-016-0749-9.

M. S. Moran et al., “Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer.” Int. J. Radiat. Oncol. Biol. Phys., vol. 88, no. 3, pp. 553–564, Mar. 2014, doi: 10.1016/j.ijrobp.2013.11.012.

J. E. Bekelman et al., “Uptake and costs of hypofractionated vs conventional whole breast irradiation after breast conserving surgery in the United States, 2008-2013.,” JAMA, vol. 312, no. 23, pp. 2542–2550, Dec. 2014, doi: 10.1001/jama.2014.16616.

F. De Rose et al., “Phase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2-year toxicity and clinical results.” Radiat. Oncol., vol. 11, no. 1, p. 120, Sep. 2016, doi: 10.1186/s13014-016-0701-z.

S.-S. Liau, M. Cariati, D. Noble, C. Wilson, and G. C. Wishart, “Audit of local recurrence following breast conservation surgery with 5-mm target margin and hypofractionated 40-Gray breast radiotherapy for invasive breast cancer.,” Ann. R. Coll. Surg. Engl., vol. 92, no. 7, pp. 562–568, Oct. 2010, doi: 10.1308/003588410X12699663903476.

N. Houssami, P. Macaskill, M. L. Marinovich, and M. Morrow, “The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: a meta-analysis.,” Ann. Surg. Oncol., vol. 21, no. 3, pp. 717–730, Mar. 2014, doi: 10.1245/s10434-014-3480-5.

Y.-J. Kim, K. H. Shin, and K. Kim, “Omitting Adjuvant Radiotherapy for Hormone Receptor‒Positive Early-Stage Breast Cancer in Old Age: A Propensity Score Matched SEER Analysis.,” Cancer Res. Treat., vol. 51, no. 1, pp. 326–336, Jan. 2019, doi: 10.4143/crt.2018.163.

M. Lagendijk et al., “TUmor-volume to breast-volume RAtio for improving COSmetic results in breast cancer patients (TURACOS); a randomized controlled trial.,” BMC Cancer, vol. 17, no. 1, p. 336, May 2017, doi: 10.1186/s12885-017-3280-y.

A. Ho and M. Morrow, “The evolution of the locoregional therapy of breast cancer.” Oncologist, vol. 16, no. 10, pp. 1367–1379, 2011, doi: 10.1634/theoncologist.2011-0223.

J. B. Yu et al., “Peer Influence on Physician Use of Shorter Course External Beam Radiation Therapy for Patients with Breast Cancer.” Pract. Radiat. Oncol., vol. 10, no. 2, pp. 75–83, 2020, doi: 10.1016/j.prro.2019.11.001.

M. Morrow et al., “Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ.,” Ann. Surg. Oncol., vol. 23, no. 12, pp. 3801–3810, Nov. 2016, doi: 10.1245/s10434-016-5449-z.

A. Nagai, Y. Shibamoto, M. Yoshida, K. Inoda, and Y. Kikuchi, “Intensity-modulated radiotherapy using two static ports of tomotherapy for breast cancer after conservative surgery: dosimetric comparison with other treatment methods and 3-year clinical results.” J. Radiat. Res., vol. 58, no. 4, pp. 529–536, Jul. 2017, doi: 10.1093/jrr/rrw132.

A. J. Khan et al., “Hypofractionated Postmastectomy Radiation Therapy Is Safe and Effective: First Results from a Prospective Phase II Trial.,” J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., vol. 35, no. 18, pp. 2037–2043, Jun. 2017, doi: 10.1200/JCO.2016.70.7158.

S. R. Stecklein et al., “Prospective Comparison of Toxicity and Cosmetic Outcome after Accelerated Partial Breast Irradiation with Conformal External Beam Radiotherapy or Single-Entry Multilumen Intracavitary Brachytherapy.,” Pract. Radiat. Oncol., vol. 9, no. 1, pp. e4–e13, Jan. 2019, doi: 10.1016/j.prro.2018.08.003.

J. S. Haviland et al., “Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials.” Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol., vol. 126, no. 1, pp. 155–162, Jan. 2018, doi: 10.1016/j.radonc.2017.10.033.

C. M. Fisher and R. Rabinovitch, “Frontiers in radiotherapy for early-stage invasive breast cancer.” J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., vol. 32, no. 26, pp. 2894–2901, Sep. 2014, doi: 10.1200/JCO.2014.55.1184.

J. Landercasper et al., “The American Society of Breast Surgeons and Quality Payment Programs: Ranking, Defining, and Benchmarking More Than 1 Million Patient Quality Measure Encounters.,” Ann. Surg. Oncol., vol. 24, no. 10, pp. 3093–3106, Oct. 2017, doi: 10.1245/s10434-017-5940-1.

L. Liu et al., “Comparing hypofractionated to conventional fractionated radiotherapy in postmastectomy breast cancer: a meta-analysis and systematic review.” Radiat. Oncol., vol. 15, no. 1, p. 17, Jan. 2020, doi: 10.1186/s13014-020-1463-1.

D. B. Page et al., “Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer.” NPJ breast cancer, vol. 5, p. 34, 2019, doi: 10.1038/s41523-019-0130-x.

L. He, Q. Wu, J. Xiong, Z. Su, B. Zhang, and Y. Song, “Do early HER2-overexpression breast cancer patients benefit from undergoing neoadjuvant trastuzumab and mastectomy? A meta-analysis.,” Cancer Manag. Res., vol. 11, pp. 8043–8054, 2019, doi: 10.2147/CMAR.S208319.

G. M. Freedman et al., “Five-year local control in a phase II study of hypofractionated intensity modulated radiation therapy with an incorporated boost for early stage breast cancer.,” Int. J. Radiat. Oncol. Biol. Phys., vol. 84, no. 4, pp. 888–893, Nov. 2012, doi: 10.1016/j.ijrobp.2012.01.091.

S. Tian et al., “Comparison of Mammographic Changes Across Three Different Fractionation Schedules for Early-Stage Breast Cancer.,” Int. J. Radiat. Oncol. Biol. Phys., vol. 95, no. 2, pp. 597–604, Jun. 2016, doi: 10.1016/j.ijrobp.2016.01.056.

B. M. Syed et al., “Oestrogen receptor negative early operable primary breast cancer in older women-Biological characteristics and long-term clinical outcome.” PLoS One, vol. 12, no. 12, p. e0188528, 2017, doi: 10.1371/journal.pone.0188528.

S. M. Shirvani et al., “Trends in Local Therapy Utilization and Cost for Early-Stage Breast Cancer in Older Women: Implications for Payment and Policy Reform.” Int. J. Radiat. Oncol. Biol. Phys., vol. 95, no. 2, pp. 605–616, Jun. 2016, doi: 10.1016/j.ijrobp.2016.01.059.

J. Landercasper et al., “Measures of Appropriateness and Value for Breast Surgeons and Their Patients: The American Society of Breast Surgeons Choosing Wisely (®) Initiative.,” Ann. Surg. Oncol., vol. 23, no. 10, pp. 3112–3118, Oct. 2016, doi: 10.1245/s10434-016-5327-8.

M. Doré, B. Cutuli, P. Cellier, L. Campion, and M. Le Blanc, “Hypofractionated irradiation in elderly patients with breast cancer after breast conserving surgery and mastectomy: Analysis of 205 cases.” Radiat. Oncol., vol. 10, p. 161, Aug. 2015, doi: 10.1186/s13014-015-0448-y.

P. T. Truong, I. A. Olivotto, T. J. Whelan, and M. Levine, “Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy.” C. Can. Med. Assoc. J. = J. l’Association medicale Can., vol. 170, no. 8, pp. 1263–1273, Apr. 2004, doi: 10.1503/cmaj.1031000.

A. J. Khan et al., “Three-Fraction Accelerated Partial Breast Irradiation (APBI) Delivered with Brachytherapy Applicators Is Feasible and Safe: First Results From the TRIUMPH-T Trial.” Int. J. Radiat. Oncol. Biol. Phys., vol. 104, no. 1, pp. 67–74, May 2019, doi: 10.1016/j.ijrobp.2018.12.050.

G. Tortorelli et al., “Standard or hypofractionated radiotherapy in the postoperative treatment of breast cancer: a retrospective analysis of acute skin toxicity and dose inhomogeneities.,” BMC Cancer, vol. 13, p. 230, May 2013, doi: 10.1186/1471-2407-13-230.

J. J. Cuaron, S. M. MacDonald, and O. Cahlon, “Novel applications of proton therapy in breast carcinoma.” Chinese Clin. Oncol., vol. 5, no. 4, p. 52, Aug. 2016, doi: 10.21037/cco.2016.06.04.

H.-J. Wu and P.-Y. Chu, “Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer.,” Int. J. Mol. Sci., vol. 22, no. 2, Jan. 2021, doi: 10.3390/ijms22020636.

I. J. Boero et al., “The impact of radiotherapy costs on clinical outcomes in breast cancer.” Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol., vol. 117, no. 2, pp. 393–399, Nov. 2015, doi: 10.1016/j.radonc.2015.10.004.

R. Rabinovitch et al., “RTOG 95-17, a Phase II trial to evaluate brachytherapy as the sole method of radiation therapy for Stage I and II breast carcinoma--year-5 toxicity and cosmesis.,” Brachytherapy, vol. 13, no. 1. pp. 17–22, 2014, doi: 10.1016/j.brachy.2013.08.002.

Y.-J. Cheng et al., “Long-Term Cardiovascular Risk after Radiotherapy in Women with Breast Cancer.,” J. Am. Heart Assoc., vol. 6, no. 5, May 2017, doi: 10.1161/JAHA.117.005633.

G. Valdivia, Á. Alonso-Diez, D. Pérez-Alenza, and L. Peña, “From Conventional to Precision Therapy in Canine Mammary Cancer: A Comprehensive Review.” Front. Vet. Sci., vol. 8, p. 623800, 2021, doi: 10.3389/fvets.2021.623800.

L. Tagliaferri et al., “Could a Personalized Strategy Using Accelerated Partial Breast Irradiation be an Advantage for Elderly Patients? A Systematic Review of the Literature and Multidisciplinary Opinion.,” J. Oncol., vol. 2020, p. 3928976, 2020, doi: 10.1155/2020/3928976.

S. M. Buszek et al., “Lumpectomy plus Hormone or Radiation Therapy Alone for Women Aged 70 Years or Older with Hormone Receptor-Positive Early Stage Breast Cancer in the Modern Era: An Analysis of the National Cancer Database.” Int. J. Radiat. Oncol. Biol. Phys., vol. 105, no. 4, pp. 795–802, Nov. 2019, doi: 10.1016/j.ijrobp.2019.07.052.

K. J. Borm et al., “Effect of hypofractionation on the incidental axilla dose during tangential field radiotherapy in breast cancer.” Strahlenther. Onkol., vol. 196, no. 9, pp. 771–778, Sep. 2020, doi: 10.1007/s00066-020-01636-6.

L. He, Y. Lv, Y. Song, and B. Zhang, “The prognosis comparison of different molecular subtypes of breast tumors after radiotherapy and the intrinsic reasons for their distinct radiosensitivity.,” Cancer Manag. Res., vol. 11, pp. 5765–5775, 2019, doi: 10.2147/CMAR.S213663.

A. Wöckel et al., “Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced B,” Geburtshilfe Frauenheilkd., vol. 78, no. 11, pp. 1056–1088, Nov. 2018, doi: 10.1055/a-0646-4630.

D. Krug et al., “Current controversies in radiotherapy for breast cancer.” Radiat. Oncol., vol. 12, no. 1, p. 25, Jan. 2017, doi: 10.1186/s13014-017-0766-3.

K. Dias et al., “Claudin-Low Breast Cancer; Clinical & Pathological Characteristics.” PLoS One, vol. 12, no. 1, p. e0168669, 2017, doi: 10.1371/journal.pone.0168669.

M. Brandão et al., “Healthcare use and costs in early breast cancer: a patient-level data analysis according to stage and breast cancer subtype.” ESMO open, vol. 5, no. 6, p. e000984, Nov. 2020, doi: 10.1136/esmoopen-2020-000984.

T. A. Koulis, A. Dang, C. Speers, and R. A. Olson, “Factors affecting radiotherapy prescribing patterns in the post-mastectomy setting.,” Curr. Oncol., vol. 25, no. 2, pp. e146–e151, Apr. 2018, doi: 10.3747/co.25.3773.

P. Ciammella et al., “Toxicity and cosmetic outcome of hypofractionated whole-breast radiotherapy: predictive clinical and dosimetric factors.” Radiat. Oncol., vol. 9, p. 97, Apr. 2014, doi: 10.1186/1748-717X-9-97.

G. G. Hanna and A. M. Kirby, “Intraoperative radiotherapy in early stage breast cancer: potential indications and evidence to date.,” Br. J. Radiol., vol. 88, no. 1049, p. 20140686, May 2015, doi: 10.1259/bjr.20140686.

M. Guenzi et al., “Hypofractionated irradiation of infra-supraclavicular lymph nodes after axillary dissection in patients with breast cancer post-conservative surgery: impact on late toxicity.” Radiat. Oncol., vol. 10, p. 177, Aug. 2015, doi: 10.1186/s13014-015-0480-y.

H. Kim et al., “Optimal radiation dose for patients with one to three lymph node positive breast cancer following breast-conserving surgery and anthracycline plus taxane-based chemotherapy: A retrospective multicenter analysis (KROG 1418).,” Oncotarget, vol. 8, no. 1, pp. 1796–1804, Jan. 2017, doi: 10.18632/oncotarget.12882.

H. S. Choi, H. S. Jang, K. M. Kang, and B.-O. Choi, “Symptom palliation of hypofractionated radiotherapy for patients with incurable inflammatory breast cancer.” Radiat. Oncol., vol. 14, no. 1, p. 110, Jun. 2019, doi: 10.1186/s13014-019-1320-2.

W. Budach et al., “DEGRO practical guidelines for radiotherapy of breast cancer V: Therapy for locally advanced and inflammatory breast cancer, as well as local therapy in cases with synchronous distant metastases.” Strahlenther. Onkol., vol. 191, no. 8, pp. 623–633, Aug. 2015, doi: 10.1007/s00066-015-0843-1.

K. Karasawa et al., “A Phase I clinical trial of carbon ion radiotherapy for Stage I breast cancer: clinical and pathological evaluation.” J. Radiat. Res., vol. 60, no. 3, pp. 342–347, May 2019, doi: 10.1093/jrr/rry113.

M. A. Torres et al., “The Impact of Axillary Lymph Node Surgery on Breast Skin Thickening During and After Radiation Therapy for Breast Cancer.” Int. J. Radiat. Oncol. Biol. Phys., vol. 95, no. 2, pp. 590–596, Jun. 2016, doi: 10.1016/j.ijrobp.2016.01.030.

R. Kreienberg, U.-S. Albert, M. Follmann, I. B. Kopp, T. Kühn, and A. Wöckel, “Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012.,” Geburtshilfe Frauenheilkd., vol. 73, no. 6, pp. 556–583, Jun. 2013, doi: 10.1055/s-0032-1328689.

L. Feys et al., “Radiation-induced lung damage promotes breast cancer lung-metastasis through CXCR4 signaling.” Oncotarget, vol. 6, no. 29, pp. 26615–26632, Sep. 2015, doi: 10.18632/oncotarget.5666.

M. Maes-Carballo, L. Mignini, M. Martín-Díaz, A. Bueno-Cavanillas, and K. S. Khan, “Quality and reporting of clinical guidelines for breast cancer treatment: A systematic review.” Breast, vol. 53, pp. 201–211, Oct. 2020, doi: 10.1016/j.breast.2020.07.011.

M. Gray et al., “Naturally-Occurring Canine Mammary Tumors as a Translational Model for Human Breast Cancer.” Front. Oncol., vol. 10, p. 617, 2020, doi: 10.3389/fonc.2020.00617.

K. P. Valuckas, V. Atkocius, I. Kuzmickiene, E. Aleknavicius, S. Liukpetryte, and V. Ostapenko, “Second malignancies following conventional or combined 252Cf neutron brachytherapy with external beam radiotherapy for breast cancer.,” J. Radiat. Res., vol. 54, no. 5, pp. 872–879, Sep. 2013, doi: 10.1093/jrr/rrt009.

K. M. Arnold, L. M. Opdenaker, N. J. Flynn, D. K. Appeah, and J. Sims-Mourtada, “Radiation induces an inflammatory response that results in STAT3-dependent changes in cellular plasticity and radioresistance of breast cancer stem-like cells.,” Int. J. Radiat. Biol., vol. 96, no. 4, pp. 434–447, Apr. 2020, doi: 10.1080/09553002.2020.1705423.

V. Landoni et al., “Evidence from a breast cancer hypofractionated schedule: late skin toxicity assessed by ultrasound.” J. Exp. Clin. Cancer Res., vol. 32, no. 1, p. 80, Oct. 2013, doi: 10.1186/1756-9966-32-80.

Y. Hasan, J. Waller, K. Yao, S. J. Chmura, and D. Huo, “Utilization trend and regimens of hypofractionated whole breast radiation therapy in the United States.,” Breast Cancer Res. Treat., vol. 162, no. 2, pp. 317–328, Apr. 2017, doi: 10.1007/s10549-017-4120-0.

C. W. Swanick et al., “Long-term Patient-Reported Outcomes in Older Breast Cancer Survivors: A Population-Based Survey Study.” Int. J. Radiat. Oncol. Biol. Phys., vol. 100, no. 4, pp. 882–890, Mar. 2018, doi: 10.1016/j.ijrobp.2017.11.047.

J. S. Chang et al., “Trends in the Application of Postmastectomy Radiotherapy for Breast Cancer With 1 to 3 Positive Axillary Nodes and Tumors ≤5 cm in the Modern Treatment Era: A Retrospective Korean Breast Cancer Society Report.,” Medicine (Baltimore)., vol. 95, no. 19, p. e3592, May 2016, doi: 10.1097/MD.0000000000003592.

M. Scorsetti et al., “Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments.,” Radiat. Oncol., vol. 7, p. 145, Aug. 2012, doi: 10.1186/1748-717X-7-145.

I. Ratosa, A. Jenko, and I. Oblak, “Breast size impact on adjuvant radiotherapy adverse effects and dose parameters in treatment planning.” Radiol. Oncol., vol. 52, no. 3, pp. 233–244, Aug. 2018, doi: 10.2478/raon-2018-0026.

S. Ahmed et al., “Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2.,” Nat. Genet., vol. 41, no. 5, pp. 585–590, May 2009, doi: 10.1038/ng.354.

S. Prathima, R. Kalyani, and S. Parimala, “Primary tubercular mastitis masquerading as malignancy.” Journal of natural science, biology, and medicine, vol. 5, no. 1. pp. 184–186, Jan-2014, doi: 10.4103/0976-9668.127324.

Z. Güzelöz et al., “Treatment results in patients with ductal carcinoma in situ treated with adjuvant radiotherapy.,” Turkish J. Med. Sci., vol. 49, no. 4, pp. 1151–1156, Aug. 2019, doi: 10.3906/sag-1810-53.

C. Murphy et al., “Impact of the radiation boost on outcomes after breast-conserving surgery and radiation.” Int. J. Radiat. Oncol. Biol. Phys., vol. 81, no. 1, pp. 69–76, Sep. 2011, doi: 10.1016/j.ijrobp.2010.04.067.

S. Darby et al., “Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.” Lancet (London, England), vol. 378, no. 9804, pp. 1707–1716, Nov. 2011, doi: 10.1016/S0140-6736(11)61629-2.

S.-W. Lee et al., “Accelerated whole breast irradiation in early breast cancer patients with adverse prognostic features.” Oncotarget, vol. 7, no. 49, pp. 81888–81898, Dec. 2016, doi: 10.18632/oncotarget.11702.

S. Ahlawat et al., “Short-Course Hypofractionated Radiation Therapy with Boost in Women with Stages 0 to IIIa Breast Cancer: A Phase 2 Trial.” Int. J. Radiat. Oncol. Biol. Phys., vol. 94, no. 1, pp. 118–125, Jan. 2016, doi: 10.1016/j.ijrobp.2015.09.011.

M. S. Moran et al., “Association of Radiotherapy Boost for Ductal Carcinoma in Situ with Local Control After Whole-Breast Radiotherapy.,” JAMA Oncol., vol. 3, no. 8, pp. 1060–1068, Aug. 2017, doi: 10.1001/jamaoncol.2016.6948.

E. Ippolito et al., “Hypofractionated radiotherapy with concomitant boost for breast cancer: a dose escalation study.” Br. J. Radiol., vol. 92, no. 1095, p. 20180169, Mar. 2019, doi: 10.1259/bjr.20180169.

S. Park, S. Do Ahn, E. K. Choi, and S. S. Kim, “The effect of escalating the boost dose for patients with involved resection margin after breast-conserving surgery.” Jpn. J. Clin. Oncol., vol. 48, no. 3, pp. 272–277, Mar. 2018, doi: 10.1093/jjco/hyy002.

M. C. De Santis et al., “Comparison of two radiation techniques for the breast boost in patients undergoing neoadjuvant treatment for breast cancer.,” Br. J. Radiol., vol. 89, no. 1066, p. 20160264, Oct. 2016, doi: 10.1259/bjr.20160264.

P. Pinnarò et al., “Short course hypofractionated whole breast irradiation after conservative surgery: a single institution phase II study.” J. Exp. Clin. Cancer Res., vol. 36, no. 1, p. 191, Dec. 2017, doi: 10.1186/s13046-017-0640-z.

I. Kindts, A. Laenen, T. Depuydt, and C. Weltens, “Tumour bed boost radiotherapy for women after breast-conserving surgery.” Cochrane database Syst. Rev., vol. 11, no. 11, p. CD011987, Nov. 2017, doi: 10.1002/14651858.CD011987.pub2.

N. Bromham, M. Schmidt-Hansen, M. Astin, E. Hasler, and M. W. Reed, “Axillary treatment for operable primary breast cancer.,” Cochrane database Syst. Rev., vol. 1, no. 1, p. CD004561, Jan. 2017, doi: 10.1002/14651858.CD004561.pub3.

E. Phillips, “MEDICAL PRELIMINARIES FOR LONDON STUDENTS.” British Medical Journal, vol. 1, no. 2686. p. 1456, Jun-1912.

H. A. Jones et al., “Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial.” J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., vol. 27, no. 30, pp. 4939–4947, Oct. 2009, doi: 10.1200/JCO.2008.21.5764.

J. Nsaful et al., “Experiences and challenges in the management of pregnancy-associated breast cancer at the Korle Bu Teaching Hospital: a review of four cases.” Ecancermedicalscience, vol. 14. p. 1140, 2020, doi: 10.3332/ecancer.2020.1140.

D. J. Klionsky et al., “Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).,” Autophagy, vol. 12, no. 1, pp. 1–222, 2016, doi: 10.1080/15548627.2015.1100356.

J. Sun, Z. Huang, Z. Hu, and R. Sun, “Benefits of local tumor excision and pharyngectomy on the survival of nasopharyngeal carcinoma patients: a retrospective observational study based on SEER database.,” J. Transl. Med., vol. 15, no. 1, p. 116, May 2017, doi: 10.1186/s12967-017-1204-x.

L.-S. Zheng et al., “SPINK6 Promotes Metastasis of Nasopharyngeal Carcinoma via Binding and Activation of Epithelial Growth Factor Receptor.,” Cancer Res., vol. 77, no. 2, pp. 579–589, Jan. 2017, doi: 10.1158/0008-5472.CAN-16-1281.


How to Cite
Khatun, R. A., Khatun, J., & Ahamed, K. U. (2021). Extended Hypofractionated Cancer Radiation Therapy Against Aged and Non-aged Breast Carcinomas Patients. European Journal of Clinical Medicine, 2(3), 122–129. https://doi.org/10.24018/clinicmed.2021.2.3.59